FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1806-1809 May 1, 2003 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In the State of the Union address of January 2003, President George W. Bush announced an unprecedented five-year, $15 billion Emergency Plan for AIDS Relief¹ to provide highly active antiretroviral therapy (HAART) to up to 2 million patients infected with the human immunodeficiency virus (HIV) in Africa and the Caribbean. Such efforts are urgently needed to offer hope to the more than 24 million HIV-infected persons living in settings where medical and economic resources are limited. The availability of generic HAART formulations has facilitated efforts mediated by the Joint United Nations Programme on HIV/AIDS (UNAIDS) to encourage multinational pharmaceutical manufacturers . . . [Full Text of this Article]

The Need for Trained HIV Care Providers

Infrastructure Requirements for the Use of HAART

Antiretroviral Resistance

Improving Treatment Guidelines

Providing HAART

HIV Therapy Combined with Primary Care and Prevention

The Priorities

Source Information

From the Division of Infectious Diseases, Johns Hopkins Medical School, Baltimore (S.J.R., J.G.B., R.C.B.); the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. (T.C.Q.); and the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore (C.B.).

Related Letters:

The AIDS Pandemic
Fielder J. F., Gribble R. K., Mujeeb S. A., Altaf A., Reynolds S. J., Quinn T. C., Bollinger R. C.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:814-815, Aug 21, 2003. Correspondence

This article has been cited by other articles:

• Desvarieux, M., Landman, R., Liautaud, B., Girard, P.-M., for the INTREPIDE Initiative In Global Health, (2005). Antiretroviral Therapy in Resource-Poor Countries: Illusions and Realities. Am. J. Public Health 95: 1117-1122 [Abstract] [Full Text]  
• Sande, M. A., Ronald, A. (2004). Treatment of HIV/AIDS: Do the Dilemmas Only Increase?. JAMA 292: 266-268 [Full Text]  
• Siddappa, N. B., Dash, P. K., Mahadevan, A., Jayasuryan, N., Hu, F., Dice, B., Keefe, R., Satish, K. S., Satish, B., Sreekanthan, K., Chatterjee, R., Venu, K., Satishchandra, P., Ravi, V., Shankar, S. K., Shankarappa, R., Ranga, U. (2004). Identification of Subtype C Human Immunodeficiency Virus Type 1 by Subtype-Specific PCR and Its Use in the Characterization of Viruses Circulating in the Southern Parts of India. J. Clin. Microbiol. 42: 2742-2751 [Abstract] [Full Text]  
• Fielder, J. F., Gribble, R. K., Mujeeb, S. A., Altaf, A., Reynolds, S. J., Quinn, T. C., Bollinger, R. C. (2003). The AIDS Pandemic. NEJM 349: 814-815 [Full Text]